Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Proteome SciencesPMSNF 12-1 Month Momentum % is -44.88% as of Jul. 24, 2026. The stock has 6 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Proteome Sciences ranks worse than 88.32% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-07-24), Proteome Sciences's 12-1 Month Momentum % is -44.88%.
The industry rank for Proteome Sciences's 12-1 Month Momentum % or its related term are showing as below:
PMSNF's 12-1 Month Momentum % is ranked worse than 88.32% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -7.41
vs PMSNF: -44.88
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Proteome Sciences 12-1 Month Momentum % Related Terms
PMSNF vs TMO, DHR, IDXX: 12-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences 12-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -44.88% mean?
Proteome Sciences (PMSNF) has a 12-1 Month Momentum % of -44.88% as of Jul. 24, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Proteome Sciences and its competitors. According to the industry distribution chart, Proteome Sciences ranks #189 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 88.3%.
Is Proteome Sciences' 12-1 Month Momentum % too high?
Proteome Sciences' current 12-1 Month Momentum % is -44.88%. Based on the distribution chart, Proteome Sciences ranks #189 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Proteome Sciences' 12-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #189 out of 214 companies for 12-1 Month Momentum %. This places Proteome Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 12-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current 12-1 Month Momentum % is -44.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (PMSNF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 32.5% below its estimated fair value. The current 12-1 Month Momentum % is -44.88%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For Proteome Sciences (PMSNF), the current 12-1 Month Momentum % is -44.88% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMSNF has been successfully added to your 
